文献速递消化道肿瘤与早癌消化内镜

符合美国医疗保险和医疗补助服务中心覆盖标准的血液检测用于结直肠癌筛查的有效性与成本效果

Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
PubMed 文献 · Gastroenterology · 2024-03-26

研究采用三种结直肠癌微模拟模型,评估45至75岁每三年一次血液筛查(按美国医疗保险和医疗补助服务中心最低性能标准:灵敏度74%、特异度90%)与不筛查、每年粪便免疫化学检测、每三年粪便DNA检测联合粪便免疫化学检测及每10年结肠镜筛查相比的有效性和成本效果。结果显示血液筛查相比不筛查具有成本效果,但与现有筛查策略相比效果更低且成本更高,即使其参与率提高20个百分点,粪便免疫化学检测仍更有效且成本更低。

要点

  • 血液筛查相比不筛查具有成本效果,每获得一个质量调整生命年需额外花费25,600至43,700美元。
  • 与粪便免疫化学检测、粪便DNA检测联合粪便免疫化学检测及结肠镜相比,血液筛查效果更低且成本更高。
  • 即使血液筛查参与率比粪便免疫化学检测高20个百分点,粪便免疫化学检测仍更有效且成本更低。

核心结论

  • 即使筛查参与率更高,按美国医疗保险和医疗补助服务中心规定的最低性能标准(灵敏度74%、特异度90%)每三年一次血液筛查,与现有结直肠癌筛查策略相比,预计不具有成本效果。

研究设计与样本

  • 研究使用三种结直肠癌微模拟模型(MISCAN-Colon、CRC-SPIN和SimCRC)评估45至75岁每三年一次血液筛查的有效性和成本效果。
  • 血液筛查与不筛查、每年粪便免疫化学检测、每三年粪便DNA检测联合粪便免疫化学检测以及每10年结肠镜筛查进行比较。
  • 敏感性分析中变化了筛查年龄、检测性能特征和筛查参与率。

主要发现

  • 与不筛查相比,血液筛查具有成本效果,每获得一个质量调整生命年需额外花费25,600至43,700美元。
  • 与粪便免疫化学检测、粪便DNA检测联合粪便免疫化学检测及结肠镜相比,血液筛查不具有成本效果,质量调整生命年减少且成本增加。

关键数值与推荐

  • 美国医疗保险和医疗补助服务中心覆盖的血液检测标准为:检测结直肠癌的灵敏度至少74%,特异度至少90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A blood-based colorectal cancer (CRC) screening test may increase screening participation. However, blood tests may be less effective than current guideline-endorsed options. The Centers for Medicare & Medicaid Services (CMS) covers blood tests with sensitivity of at least 74% for detection of CRC and specificity of at least 90%. In this study, we investigate whether a blood test that meets these criteria is cost-effective. METHODS: Three microsimulation models for CRC (MISCAN-Colon, CRC-SPIN, and SimCRC) were used to estimate the effectiveness and cost-effectiveness of triennial blood-based screening (from ages 45 to 75 years) compared to no screening, annual fecal immunochemical testing (FIT), triennial stool DNA testing combined with an FIT assay, and colonoscopy screening every 10 years. The CMS coverage criteria were used as performance characteristics of the hypothetical blood test. We varied screening ages, test performance characteristics, and screening uptake in a sensitivity analysis. RESULTS: Without screening, the models predicted 77-88 CRC cases and 32-36 CRC deaths per 1000 individuals, costing $5.3-$5.8 million. Compared to no screening, blood-based screening was cost-effective, with an additional cost of $25,600-$43,700 per quality-adjusted life-year gained (QALYG). However, compared to FIT, triennial stool DNA testing combined with FIT, and colonoscopy, blood-based screening was not cost-effective, with both a decrease in QALYG and an increase in costs. FIT remained more effective (+5-24 QALYG) and less costly (-$3.2 to -$3.5 million) than blood-based screening even when uptake of blood-based screening was 20 percentage points higher than uptake of FIT. CONCLUSION: Even with higher screening uptake, triennial blood-based screening, with the CMS-specified minimum performance sensitivity of 74% and specificity of 90%, was not projected to be cost-effective compared with established strategies for colorectal cancer screening.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. van den Puttelaar R, Nascimento de Lima P, Knudsen AB, et al. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision. Gastroenterology. 2024. PMID: 38552671. doi:10.1053/j.gastro.2024.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。